Thrap 3 docks on phosphoserine 273 of PPAR γ and controls diabetic gene programming

Genes and Development

Volumn 28, Issue 21, 2014, Pages 2361-2369

  Choi, Jang Hyun ^a   Choi, Sun Sil ^a   Kim, Eun Sun ^a   Jedrychowski, Mark P ^b   Yang, Yong Ryoul ^a   Jang, Hyun Jun ^a   Suh, Pann Ghill ^a   Banks, Alexander S ^b   Gygi, Steven P ^b   Spiegelman, Bruce M ^b  

^a Ulsan National Institute of Science and Technology   (South Korea)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Energy homeostasis; Gene reprogramming; Phosphorylation; PPAR ; Thrap3 interaction

Indexed keywords

ADIPONECTIN; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENT FACTOR D; CYCLIN DEPENDENT KINASE 5; PEPTIDES AND PROTEINS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THYROID HORMONE RECEPTOR ASSOCIATED PROTEIN 3; UNCLASSIFIED DRUG; ADIPOCYTOKINE; DNA BINDING PROTEIN; PHOSPHOSERINE; PROTEIN BINDING; THRAP3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GENE CONTROL; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; HYPERGLYCEMIA; INSULIN RESISTANCE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; 3T3 CELL LINE; ANIMAL; C57BL MOUSE; CELL CULTURE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEK293 CELL LINE; HUMAN; MALE; METABOLISM; PHOSPHORYLATION;

3T3 CELLS; ADIPOKINES; ANIMALS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 5; DIABETES MELLITUS, TYPE 2; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PHOSPHOSERINE; PPAR GAMMA; PROTEIN BINDING; TRANSCRIPTION FACTORS;

EID: 84908416698     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.249367.114     Document Type: Article

References (48)

1. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7: 947–953.
2. Bray GA, Bellanger T. 2006. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 29: 109–117.
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med 348: 1625–1638.
4. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F. 1998. Structure of the intact PPAR-γ–RXR–nuclear receptor complex on DNA. Nature 456: 350–356.
5. Chen JD, Evans RM. 1995. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377: 454–457.
6. Choi JH, Banks AS, Estall JL, Kajimura S, Boström P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Blüher M, et al. 2010. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5. Nature 466: 451–456.
7. Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, Kuruvilla DS, Shin Y, He Y, Bruning JB, et al. 2011. Anti-diabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477: 477–481.
8. Cook KS, Min HY, Johnson D, Chaplinsky RJ, Flier JS, Hunt CR, Spiegelman BM. 1987. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science 237: 402–405.
9. DiRenzo J, Söderstrom M, Kurokawa R, Ogliastro MH, Ricote M, Ingrey S, Hörlein A, Rosenfeld MG, Glass CK. 1997. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol 17: 2166–2176.
10. Flier JS, Cook KS, Usher P, Spiegelman BM. 1987. Severely impaired adipsin expression in genetic and acquired obesity. Science 237: 405–408.
11. Fondell JD, Ge H, Roeder RG. 1996. Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. Proc Natl Acad Sci 93: 8329–8333.
12. Fondell JD, Guermah M, Malik S, Roeder RG. 1999. Thyroid hormone receptor-associated proteins and general positive cofactors mediate thyroid hormone receptor function in the absence of the TATA box-binding protein-associated factors of TFIID. Proc Natl Acad Sci 96: 1959–1964.
13. Ge K, Guermah M, Yuan CX, Ito M, Wallberg AE, Spiegelman BM, Roeder RG. 2002. Transcription coactivator TRAP220 is required for PPARγ2-stimulated adipogenesis. Nature 417: 563–567.
14. Heyd F, Lynch KW. 2010. Phosphorylation-dependent regulation of PSF by GSK3 controls CD45 alternative splicing. Mol Cell 40: 126–137.
15. Hörlein AJ, Näär AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Söderström M, Glass CK, et al. 1995. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377: 397–404.
16. Hotamisligil GS, Shargill NS, Spiegelman BM. 1993. Adipose expression of tumor necrosis factor-a: direct role in obesitylinked insulin resistance. Science 259: 87–91.
17. Hsu IR, Kim SP, Kabir M, Bergman RN. 2007. Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr 86: 867–871.
18. Hu E, Liang P, Spiegelman BM. 1996. AdipoQ is a novel adiposespecific gene dysregulated in obesity. J Biol Chem 271: 10697–10703.
19. Ito M, Yuan CX, Malik S, Gu W, Fondell JD, Yamamura S, Fu ZY, Zhang X, Qin J, Roeder RG. 1999. Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol Cell 3: 361–370.
20. Ito M, Okano HJ, Darnell RB, Roeder RG. 2002. The TRAP100 component of the TRAP/Mediator complex is essential in broad transcriptional events and development. EMBO J 21: 3464–3475.
21. Katano-Toki A, Satoh T, Tomaru T, Yoshino S, Ishizuka T, Ishii S, Ozawa A, Shibusawa N, Tsuchiya T, Saito T, et al. 2013. THRAP3 interacts with HELZ2 and plays a novel role in adipocyte differentiation. Mol Endocrinol 27: 769–780.
22. Kershaw EE, Flier JS. 2004. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548–2556.
23. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G, et al. 2007. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 117: 2621–2637.
24. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. 1992. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355: 446–449.
25. Kumashiro N, Beddow SA, Vatner DF, Majumdar SK, Cantley JL, Guebre-Egziabher F, Fat I, Guigni B, Jurczak MJ, Birkenfeld AL, et al. 2013. Targeting pyruvate carboxylase reduces gluconeogenesis and adiposity and improves insulin resistance. Diabetes 62: 2183–2194.
26. Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard- Boulangé A, Capeau J, Caron M. 2006. Long-term treatment with interleukin-1b induces insulin resistance in murine and human adipocytes. Diabetologia 49: 2162–2173.
27. Lande-Diner L, Boyault C, Kim JY, Weitz CJ. 2013. A positive feedback loop links circadian clock factor CLOCK–BMAL1 to the basic transcriptional machinery. Proc Natl Acad Sci 110: 16021–16026.
28. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor g (PPARγ). J Biol Chem 270: 12953–12956.
29. Li P, Fan W, Xu J, Lu M, Yamamoto H, Auwerx J, Sears DD, Talukdar S, Oh D, Chen A, et al. 2011. Adipocyte NCoR knockout decreases PPARγ phosphorylation and enhances PPARγ activity and insulin sensitivity. Cell 147: 815–826.
30. Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA. 2007. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298: 2634–2643.
31. Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, Kelly ME, Chatterjee Bhowmick D, Murano I, Cohen P, et al. 2014. Adipsin is an adipokine that improves b cell function in diabetes. Cell 158: 41–53.
32. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, et al. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8: 731–737.
33. Mangelsdorf DJ, Evans RM. 1995. The RXR heterodimers and orphan receptors. Cell 83: 841–850.
34. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. 2001. Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA 289: 76–79.
35. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, et al. 2004. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27: 256–263.
36. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV. 1998. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-g. Nature 395: 137–143.
37. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. 1998. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92: 829–839.
38. Rosen ED, Spiegelman BM. 2014. What we talk about when we talk about fat. Cell 156: 20–44.
39. Rosen BS, Cook KS, Yaglom J, Groves DL, Volanakis JE, Damm D, White T, Spiegelman BM. 1989. Adipsin and complement factor D activity: an immune-related defect in obesity. Science 244: 1483–1487.
40. Tontonoz P, Spiegelman BM. 2008. Fat and beyond: the diverse biology of PPARγ. Annu Rev Biochem 77: 289–312.
41. Tontonoz P, Hu E, Spiegelman BM. 1994. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79: 1147–1156.
42. Trujillo ME, Scherer PE. 2006. Adipose tissue-derived factors: impact on health and disease. Endocr Rev 27: 762–778.
43. Unger RH. 2002. Lipotoxic diseases. Annu Rev Med 53: 319–336.
44. Van Gaal LF, Mertens IL, De Block CE. 2006. Mechanisms linking obesity with cardiovascular disease. Nature 444: 875–880.
45. Watts LM, Manchem VP, Leedom TA, Rivard AL, McKay RA, Bao D, Neroladakis T, Monia BP, Bodenmiller DM, Cao JX, et al. 2005. Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54: 1846–1853.
46. Willson TM, Lambert MH, Kliewer SA. 2001. Peroxisome proliferator-activated receptor g and metabolic disease. Annu Rev Biochem 70: 341–367.
47. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, et al. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941–946.
48. Yuan CX, Ito M, Fondell JD, Fu ZY, Roeder RG. 1998. The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. Proc Natl Acad Sci 95: 7939–7944.